National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments by Gelfand, Joel M. et al.






















1254National Psoriasis Foundation COVID-19
Task Force guidance for management of
psoriatic disease during the pandemic:
Version 2dAdvances in psoriatic disease
management, COVID-19 vaccines, and
COVID-19 treatmentsJoel M. Gelfand, MD, MSCE,a,b April W. Armstrong, MD, MPH,c Stacie Bell, PhD,d
George L. Anesi, MD, MSCE, MBE,b,e Andrew Blauvelt, MD, MBA,f Cassandra Calabrese, DO,g
Erica D. Dommasch, MD, MPH,h Steven R. Feldman, MD, PhD,i Dafna Gladman, MD, FRCPC,j,k
Leon Kircik, MD,l,m Mark Lebwohl, MD,l Vincent Lo Re III, MD, MSCE,b,n George Martin, MD,o
Joseph F. Merola, MD, MMSc,p Jose U. Scher, MD,q Sergio Schwartzman, MD,r James R. Treat, MD,s
Abby S. Van Voorhees, MD,t Christoph T. Ellebrecht, MD,a Justine Fenner, MD,l Anthony Ocon, MD, PhD,u
Maha N. Syed, MBBS,a Erica J. Weinstein, MD,n George Gondo, MA,d Sue Heydon, MA,d
Samantha Koons, BS,d and Christopher T. Ritchlin, MD, MPHu
Philadelphia, Pennsylvania; Los Angeles, California; Portland, Oregon; Cleveland, Ohio; Boston,
Massachusetts; Winston-Salem, North Carolina; Toronto, Ontario, Canada; New York and Rochester,
New York; Indianapolis, Indiana; Maui, Hawaii; and Norfolk, VirginiaObjective: To update guidance regarding the management of psoriatic disease during the COVID-19
pandemic.Study Design: The task force (TF) includes 18 physician voting members with expertise in dermatology,
rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting
members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the
psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A
Delphi process was conducted.ent of Dermatology, University of Pennsylvania
ool of Medicine, Philadelphiaa; Department of
pidemiology and Informatics and Center for
miology and Biostatistics Perelman School of
versity of Pennsylvania, Philadelphiab; Depart-
atology, Keck School of Medicine, University of
ornia, Los Angelesc; National Psoriasis Founda-
; Division of Pulmonary, Allergy, and Critical Care,
Pennsylvania Perelman School of Medicine,
Oregon Medical Research Center, Portlandf;
f Rheumatology and Immunology, Cleveland
ment of Dermatology, Harvard Medical School,
rtment of Dermatology, Wake Forest School of
ston-Salemi; Krembil Research Institute, Toronto
italj; University of Toronto, Psoriatic Arthritis
ersity Health Network, Toronto Western Hospi-
nt of Dermatology, Icahn School of Medicine at
New Yorkl; Indiana University Medical Center,
Division of Infectious Diseases, University of
Perelman School of Medicine, Philadelphian;
ssociates, Mauio; Brigham and Women’s Hospi-
edical School, Bostonp; Department of Medicine,
Division of Rheumatology, New York University Grossman
School of Medicine and New York University Langone Ortho-
pedic Hospital, New Yorkq; Department of Rheumatology,
Hospital for Special Surgery, New Yorkr; Department of
Pediatric Dermatology, Children’s Hospital of Philadelphias;
Department of Dermatology, Eastern Virginia Medical School,
Norfolkt; and Division of Allergy, Immunology, and Rheuma-
tology Division, University of Rochester Medical Center.u
Funding sources: None.
IRB approval status: Not applicable.
Accepted for publication December 29, 2020.
Reprints not available from the authors.
Correspondence to: Joel M. Gelfand, MD, MSCE, Department of
Dermatology, 3400 Civic Center Blvd, Perelman Center for
Advanced Medicine, Philadelphia, PA 19104. E-mail: Joel.
Gelfand@pennmedicine.upenn.edu.
Published online January 7, 2021.
0190-9622/$36.00
 2021 by the American Academy of Dermatology, Inc.
https://doi.org/10.1016/j.jaad.2020.12.058.)
J AM ACAD DERMATOL
VOLUME 84, NUMBER 5
Gelfand et al 1255Results: The TF updated evidence for the original 22 statements and added 5 new recommendations. The
average of the votes was within the category of agreement for all statements, 13 with high consensus and 14
with moderate consensus.Limitations: The evidence behind many guidance statements is variable in quality and/or quantity.Conclusions: These statements provide guidance for the treatment of patients with psoriatic disease on
topics including how the disease and its treatments affect COVID-19 risk, how medical care can be
optimized during the pandemic, what patients should do to lower their risk of getting infected with severe
acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they
develop COVID-19. The guidance is a living document that is continuously updated by the TF as data
emerge. ( J Am Acad Dermatol 2021;84:1254-68.)
Key words: biologics; COVID-19; psoriasis; psoriatic arthritis; SARS-CoV-2; vaccines.CAPSULE SUMMARY
d The National Psoriasis Foundation
COVID-19 Task Force produced 27
guidance statements to promote
optimal management of psoriatic
disease during the pandemic.
d Shared decision making, adherence to
evidence-based treatment, and the
urgent use of novel COVID-19
vaccination are recommended. The
guidance statements will be updated in
accordance with the rapidly evolving
science of COVID-19.The COVID-19 pandemic
has substantially worsened
since the publication of




September 4, 2020.1 In just
the ensuing 15 weeks alone,
there have been more than
an additional 11,100,000
cases and 125,000 COVID-
19 deaths in the United
States and an additional
nearly 50,000,000 cases and
more than 800,000 deaths
worldwide.2 Similar to the
exponential growth of
COVID-19 cases, basic biological and epidemiologic
knowledge related to this pandemic have expanded
dramatically. In just a few months since our initial
recommendations, there have been major advances
in the understanding of how to prevent and treat
COVID-19 as well as a substantial increase in data to
inform management decisions for patients with pso-
riatic disease during the pandemic. Therefore, this TF
is providing updated scientifically based guidance to
promote optimal management of psoriatic disease
during the pandemic.
METHODS
The methods have been described in detail
previously.1 Briefly, the COVID-19 TF includes
physicians, fellows, and senior NPF staff with a
variety of expertise relevant to decision making in
the pandemic. The TF reviews COVID-19 literature
weekly in relation to psoriatic disease and meets
every 2 to 4 weeks to address 5 core questionsrelated to the pandemic.
Existing recommendations
were updated based on
evolving science and were
approved by unanimous
consent. New recommenda-
tions were generated by us-
ing a modified Delphi
process based on the RAND
appropriateness method,
including 2 rounds of voting
with discussion in between.3
(Only 1 round was used for
new recommendations that
achieved high consensus on
the first round.) Panel
consensus was determined
to be low when 5 or morevotes fell into the 1-to-3 rating range with 5 or more
votes concurrently falling into the 7-to-9 rating range.
Consensus was interpreted as high if all 18 votes fell
within a single tertile, with all other combinations
considered as moderate levels of consensus. The
results were analyzed by the NPF with an indepen-
dent analysis of the data by a nonvoting member of
the TF.RESULTS
The TF reaffirms the initial 22 guidance statements
with updated data and has issued 5 new recommen-
dations (Table I). The median was within the
category of agreement for all new statements, with
the number of votes outside the range of agreement
being only 2 for the 1 new statement for which
agreement was not unanimous. All guidance state-
ments were recommended, 13 with high consensus
and the 14 with moderate consensus.
Abbreviations used:
CI: confidence interval
EUA: Emergency Use Authorization
FDA: US Food and Drug Administration
IL: interleukin
mRNA: messenger RNA




SARS-CoV-2: severe acute respiratory syndrome
coronavirus 2
TF: Task Force
TNFi: tumor necrosis factor inhibitors
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disease itself on severe acute respiratory
syndrome coronavirus 2 infection and
COVID-19 illness?
Patients with psoriasis are more prone to
thrombosis and comorbidities that portend worse
COVID-19 outcomes andmay bemore susceptible to
infection, which raised concerns that they could be at
increased risk for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection and worse
COVID-19 outcomes.4-8 Nevertheless, patients with
psoriatic disease appear to have similar rates of
infection with SARS-CoV-2 and COVID-19 outcomes
as the general population, with multiple new studies
from Italy, which primarily focused on patients with
psoriasis receiving oral or biologic treatment,
supporting our initial recommendation (guidance
1.1).9-11 Additional new studies of patients with
psoriatic arthritis (PsA) nested within cohorts of
patients with rheumatic disease also suggest that
they have similar rates of infection with SARS-CoV-2
and COVID-19 outcomes as the general
population.12-14 However, the risk of COVID-19 in
autoimmune diseases was higher than in control
patients (odds ratio [OR], 2.19; 95% confidence
interval [CI], 1.05-4.58) in a meta-analysis of 7
case-control studies.15
The severity of COVID-19 continues to be
primarily driven by risk factors such as current
smoking, male sex, older age, and underlying
comorbidities (guidance 1.2).16-19 New data confirm
that age, male sex, and pre-existing comorbidities
are also important drivers of poor COVID-19
outcomes in patients with psoriasis.20Category 2: What are the effects of psoriasis or
PsA treatment on SARS-CoV-2 infection and
COVID-19 illness?
The evolving literature reaffirms the TF conclusion
that treatments for psoriasis and/or PsA do notappear to meaningfully alter the risk of acquiring
SARS-CoV-2 infection or having worse COVID-19
outcomes; therefore, patients who are not infected
with SARS-CoV-2 should continue their biologic or
oral therapies for psoriasis and/or PsA in most cases
(guidance 2.1 and 2.2). COVID-19 hospitalization
was more frequent in patients using nonbiologic
systemic therapy than in those using biologics (OR,
2.8; 95% CI, 1.3-6.2) in a registry of 374 patients with
psoriasis from 25 countries.20 A cohort of 6501
patients with psoriasis on biologics at northern
Italian centers showed that the standardized inci-
dence ratio of hospitalization and death in patients
with psoriasis compared with those in the general
population was 0.94 (95% CI, 0.57-1.45) and 0.42
(95% CI, 0.07-1.38), respectively.11 In a study of
12,807 patients with psoriasis on biologics from 33
Italian dermatology centers, 26 (0.25%) had
confirmed SARS-COV-2 infection (similar to general
population in Italy [0.31%]).21 In a study of patients
with psoriasis (100 on topical treatment, 80 on
biologics) from a single Italian dermatology center,
COVID-19 symptoms were more common, but not
statistically significant, in the biologic group (OR,
1.22; 95% CI, 0.58-2.58).22 A cohort of 2329 patients
with psoriasis on systemic therapy in Spain yielded
standardized incidence ratios of 1.58 (95% CI, 0.98-
2.41), 1.55 (95% CI, 0.67-3.06), and 1.38 (95% CI,
0.03-7.66) for COVID-19 cases, hospitalizations, and
deaths, respectively.23 Finally, a study of a global
electronic medical record database that includes
information on approximately 53 million people
identified no evidence for increased COVID-19 hos-
pitalization for patients prescribed tumor necrosis
factor inhibitors (TNFi) (relative risk [RR], 0.73; 95%
CI, 0.47-1.14), methotrexate (RR, 0.87; 95% CI, 0.62-
1.23), or the combination of TNFi/methotrexate (RR,
0.91; 95% CI, 0.68-1.22) within 1 year of developing
COVID-19.24
Similarly, the use of immunosuppressive/
immunomodulating therapy was not associated
with an increased risk for COVID-19 in a cohort of
5302 patients with inflammatory bowel disease.25
This finding was supported by the Surveillance
Epidemiology of Coronavirus Under Research
Exclusion (SECURE-IBD) registry, which showed
no increase in severe outcomes in patients on TNFi
or antieinterleukin (IL) 12/23 monotherapy.26
Patients with rheumatic disease do not appear to
be at higher risk of contracting SARS-CoV-2 infection
or of developing severe COVID-19 when on anti-
TNF therapy.15,27,28
Nevertheless, uncertainty remains based on the
quality of the existing data and lack of detailed
analysis of patients at high risk because of age and/or





1.1 It is not known with certainty if having psoriatic disease meaningfully alters the risks of
contracting SARS-CoV-2 (the virus that causes COVID-19 illness) or having a worse course
of COVID-19 illness. Existing data, with some exceptions, generally suggest that patients
with psoriasis and/or psoriatic arthritis have similar rates of SARS-CoV-2 infection and
COVID-19 outcomes as the general population.
Moderate
1.2 The likelihood of poor outcomes from COVID-19 is driven by risk factors such as older age
and comorbidities such as chronic heart, lung, or kidney disease and metabolic disorders
such as diabetes and obesity. Patients with psoriatic disease are more prone to these
comorbidities, particularly in those with more severe disease.
High
2.1 It is not known with certainty if treatments for psoriasis and/or psoriatic arthritis
meaningfully alter the risks of contracting SARS-CoV-2 (the virus that causes COVID-19
illness) or having a worse course of COVID-19 illness. Existing data generally suggest that
treatments for psoriasis and/or psoriatic arthritis do not meaningfully alter the risk of
acquiring SARS-CoV-2 infection or having worse COVID-19 outcomes.
Moderate
2.2 It is recommended that patients who are not infected with SARS-CoV-2 continue their
biologic or oral therapies for psoriasis and/or psoriatic arthritis in most cases. Shared
decision making between clinician and patient is recommended to guide discussions
about use of systemic therapies during the pandemic. (See guidance 2.5 for definition of
shared decision making.)
High
2.3 Chronic systemic corticosteroids should be avoided if possible for the management of
psoriatic arthritis. If patients require chronic systemic corticosteroids for the management
of psoriatic arthritis, the dose should be tapered to the lowest dose necessary to achieve
the desired therapeutic effect. Chronic systemic corticosteroid use for the treatment of
psoriatic disease at the time of acute infection with SARS-CoV-2 may be associated with
worse outcomes from COVID-19 illness. It is important to note, however, that
corticosteroids may improve outcomes for COVID-19 when initiated in hospitalized
patients requiring oxygen treatment.
High
2.4 Individuals newly diagnosed with psoriasis and/or psoriatic arthritis or who are currently not
receiving treatment should be aware that untreated psoriatic disease is associated with
serious impact on physical and emotional health and, in the case of psoriatic arthritis, can
lead to permanent joint damage and disability. Shared decision making between clinician
and patient is recommended to guide discussions about use of systemic therapies during
the pandemic. (See guidance 2.5 for definition of shared decision making.)
High
2.5 Providers recommend shared decision making with patients. Shared decision making
between clinician and patient should be guided by several factors, including the potential
benefits of treatment, the activity of skin and/or joint disease and response to previous
therapies, as well as the patient’s underlying risk for poor COVID-19 outcomes and ability
to maintain measures to prevent infection with SARS-CoV-2 such as hand hygiene,
wearing of masks, and physical distancing as required by pandemic conditions. A review
of known benefits of treatment accompanied by acknowledgment of the uncertainty
related to the COVID-19 pandemic and a discussion of a patient’s individual circumstances
and preferences should guide decision making.
Moderate
3.1 Telemedicine should be offered to manage patients wherever possible when local
restrictions or pandemic conditions limit the ability for in-person visits. The following
patients can be managed with telemedicine: Patients who are clinically stable and
previously started on psoriatic disease treatment. Patients requiring a follow-up visit and
refills for medication. New patients without timely access to in-person visits. Patients
diagnosed with COVID-19 who are experiencing a significant flare. If telemedicine visits
become inadequate to monitor patients’ disease progress or manage new or evolving
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3.2 The following patients should be considered for in-person care if pandemic conditions allow
(ie, the clinical practice is open to see patients in person) and standard operating
procedures are observed (ie, social distancing, hand washing, and masking): Patients at
risk for melanoma and nonmelanoma skin cancer should be seen in person at a frequency
consistent with the standard of care for a full skin examination. New patients establishing
care. Patients experiencing unstable psoriatic disease/flares. Patients requiring a thorough
skin/or joint examination and a full physical examination for rheumatology patients.
Moderate
3.3 Providers recommend the recent guidelines published by Lim et al35 on how to optimize
safety of office phototherapy for the patients and staff in the setting of the pandemic. See
Supplemental Table V for details.
High
4.1 Patients should be advised to follow measures that prevent infection with SARS-CoV-2.
These preventative measures include the following: to practice good hand hygiene, to
maintain physical distancing from nonhousehold members, and to wear a face covering
of the nose and mouth when indoors (except in their own home) and when outdoors but
unable to maintain physical distancing. Face coverings should not be used in children
under 2 years old due to risk of suffocation. See Supplemental Table VI for details.
High
4.2 Patients with psoriatic disease should follow measures to prevent infection with SARS-CoV-2
in the workplace. If the workplace environment does not allow for the maintenance of
prevention measures, a shared decision-making process between the patient and his/her
clinician is recommended to determine if specific accommodations are medically
necessary, especially for individuals who, due to age or underlying health conditions, are
at especially high risk for poor COVID-19 outcomes.
Moderate
4.3 Youth with psoriatic disease should follow measures to prevent infection with SARS-CoV-2
while at school. These measures include maintaining 6 feet of physical distancing,
consistently wearing masks if over the age of 2 years, and washing hands frequently. If the
school environment is unable to ensure these prevention measures or families believe
their child may not be able to adhere to these practices, we encourage discussion with
the patient, caregivers, and his/her clinician to collectively develop a learning plan in the
best interest and safety of the child.
High
4.4. Patients with psoriatic disease should receive the seasonal inactivated (eg, killed) influenza
vaccine. While this vaccine will not protect against SARS-CoV-2, influenza vaccine lowers
the risk of infection from seasonal influenza, which is of special importance to individual
and public health during the COVID-19 pandemic. Patients taking systemic medications
for psoriasis or psoriatic arthritis should discuss the timing of influenza vaccination with
respect to their systemic psoriatic medications with their health care provider in order to
optimize the response to the influenza vaccine.
High
4.5 Patients with psoriatic disease who do not have contraindications to vaccination should
receive an mRNA-based COVID-19 vaccine as soon as it becomes available to them based
on federal, state, and local guidance. Systemic medications for psoriasis or psoriatic
arthritis are not a contraindication to the mRNA-based COVID-19 vaccine. If vaccine supply
is limited, the TF recommends following the CDC’s prioritization guidelines for early
vaccination for selected groups based on their comorbidities and work setting (https://
www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations-process.html).
High
4.6 It is recommended that patients who are to receive an mRNA-based COVID-19 vaccine
continue their biologic or oral therapies for psoriasis and/or psoriatic arthritis in most
cases. Shared decision making between clinician and patient is recommended to guide
discussions about use of systemic therapies during the pandemic. (See guidance 2.5 for
definition of shared decision making.)
High
4.7 For patients with psoriatic disease deciding whether or not to participate in a COVID-19
therapeutic or vaccine clinical trial, the TF recommends that the decision should be made
on a case-by-case basis with shared decision making among the patient, researcher, and
provider.
High
5.1 Patients with psoriatic disease who become infected with SARS-CoV-2 should monitor their
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5.2 Patients with psoriatic disease who become infected with SARS-CoV-2 should be prescribed
and adhere to evidence-based COVID-19 therapies. Evidence-based therapies* currently
include supportive care for all patients and the following:
For outpatients:
d Bamlanivimab for patients meeting specific criteria and who are at high risk for
progressing to severe COVID-19 and/or hospitalization
d Casirivimab and imdevimab to be administered together for patients meeting specific




d Dexamethasone (systemic steroids) for patients meeting specific criteria
d Remdesivir treatment for patients meeting specific criteria
d Baricitinib, in combination with remdesivir, for patients meeting specific criteria
The care of the hospitalized patient should include consultation with rheumatologists,
dermatologists, and/or infectious disease specialists as medically necessary.
*Evidence-based therapies are those that have been tested in well-conducted randomized
controlled clinical trials and have proven benefit on clinically relevant COVID-19
outcomes.
5.3 Systemic corticosteroids for the management of COVID-19 in patients with psoriatic disease
are not contraindicated and should not be withheld due to the concern of potentially
flaring psoriasis upon withdrawal of corticosteroids when evidence demonstrates the
effectiveness for treating COVID-19 illness.
Moderate
5.4.1 Hydroxychloroquine or chloroquine are not recommended for the prevention or treatment
of COVID-19 in patients with psoriatic disease outside of a clinical trial. Cases of psoriasis
flare have been reported in patients on antimalarial medications, but the clinical
significance is not well understood.
High
5.4.2 At this time, due to insufficient data to recommend for or against the use of convalescent
plasma for the treatment of COVID-19 in patients with psoriatic disease, the TF
recommends convalescent plasma to primarily be used in the setting of a clinical trial.
Outside of a clinical trial, its use may be considered on a case-by-case basis with shared
decision making between the patient and provider.
Moderate
5.4.3 Ivermectin is not recommended for the prevention or treatment of COVID-19 in patients
with psoriatic disease outside of a clinical trial.
High
5.5 Resumption of psoriasis and/or psoriatic arthritis treatments held during SARS-CoV-2
infection should be decided on a case-by-case basis. Most patients can restart psoriasis
and/or psoriatic arthritis treatments after complete resolution of COVID-19 symptoms. In
those who have had a severe hospital course, shared decision making made on a case-by-
case basis is recommended.
Moderate
5.6 Patients with psoriatic disease should be aware that infection with SARS-CoV-2 may result in
a flare of psoriasis based on case reports. The clinical significance of the risk of COVID-19
flaring psoriasis is not known.
Moderate
5.7 Patients with psoriatic disease who become infected with SARS-CoV-2 should follow CDC
guidance on home isolation and discuss with their health care providers when they can
end home isolation. We recommend waiting a minimum of 10 days after COVID-19
symptom onset, along with fever resolution for 24 hours without antipyretics and
improvement in other symptoms, before ending home isolation and returning to work, as
patients are unlikely to be infectious after this point. In patients with severe cases of
COVID-19 or when psoriasis patients are on medications with immunosuppressive effects,
we recommend a case-by-case approach to determining the length of home isolation.
Moderate
5.8 Patients with close contact to someone with SARS-CoV-2 infection should quarantine
themselves for 14 days after the last contact and discuss the management of their
psoriatic disease treatment with their medical provider(s).
Moderate
CDC, Centers for Disease Control and Prevention; mRNA, messenger RNA; NPF, National Psoriasis Foundation; SARS-CoV-2, severe acute
respiratory syndrome coronavirus 2; TF, Task Force.
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1260 Gelfand et alcomorbidity; therefore, shared decision making be-
tween the clinician and patient is recommended
(guidance 2.2, 2.4, and 2.5). Chronic systemic
corticosteroids should be avoided, if possible, for
the management of PsA, because additional research
confirms that their use is associated with worse
COVID-19 outcomes (guidance 2.3).15,29
Category 3: How should medical care be
delivered to patients with psoriatic disease to
lower their risk of infection with SARS-CoV-2
while still ensuring quality of care?
Telemedicine remains a critical option for treating
patients with psoriatic disease during the pandemic
for appropriate patients (guidance 3.1 and 3.2). The
evolving literature suggests that a short interruption
of in-person patient-rheumatologist interactions had
no major detrimental impact on the disease course of
PsA as assessed by patient-reported outcomes.30
Nevertheless, reductions in in-person care during
the pandemic may be associated with a delay in
diagnosis and treatment of malignancies, including
melanoma.31,32
Universalmasking for staff, clinicians, andpatients;
restrictions on visitation; and liberal reverse transcrip-
tion polymerase chain reaction testing of symptom-
atic and asymptomatic patients are very effective in
limiting SARS-CoV-2 spread, with nosocomial trans-
mission exceptionally rare.33,34 Therefore, patients
should be informed that in-person medical care,
including phototherapy (guidance 3.3), can be deliv-
ered safely with minimal risk of COVID-19 trans-
mission in the clinical setting when safeguards are
maintained.35,36 Outbreaks in the clinical setting that
have occurred have been due to lack of masking in
patient care areas and a lack of distancing among staff
while eating unmasked.33 Thus, the TF updated
guidance 3.2, emphasizing that standard operating
procedures for social distancing, hand washing, and
masking be observed in clinical settings.
Category 4: What should patients with
psoriatic disease do to protect themselves
from becoming infected with SARS-CoV-2?
Patients should follow recommendedmeasures to
prevent infection with SARS-CoV-2 (guidance 4.1,
4.2, and 4.3).37 In cases where measures to prevent
the transmission of SARS-CoV-2 at work or school
cannot be maintained, shared decision making is
recommended to determine if specific accommoda-
tions are medically necessary (guidance 4.2 and 4.3).
In the United States, adherence rates with methods to
prevent COVID-19 were lowest among adults aged
18 to 29 years (73%) and highest among those aged
older than 60 years (86%).38 An international surveyof patients with psoriasis found that rates of
COVID-19 prevention measures were slightly higher
in those receiving biologics for psoriasis than in
those receiving nonbiologic systemic therapies.20
Since our first recommendations, the major
advance in protection from COVID-19 is the advent
of highly effective vaccines using messenger RNA
(mRNA) technology, which results in temporary
expression of the SARS-CoV-2 spike protein in
human cells after injection, triggering an immune
response (Table II). The regimen of 2 doses, 21 days
apart, for BNT162b2 (manufactured by Pfizer and
BioNTech) conferred 95% protection against
COVID-19, with an excellent safety profile similar
to that of other viral vaccines, and was granted
Emergency Use Authorization (EUA) on December
11, 2020, by the US Food and Drug Administration
(FDA).39,40 Similarly, the regimen of 2 doses, 28 days
apart, for mRNA-1273 (manufactured by Moderna)
conferred 94.5% protection against COVID-19 (FDA
EUA pending).41 Therefore, the TF recommends that
patients with psoriatic disease who do not have
contraindications to vaccination should receive an
mRNA-based COVID-19 vaccine as soon as it be-
comes available to them (guidance 4.5). Additional
vaccine platforms are undergoing testing (Table II).42
The effect of psoriasis treatment on the efficacy of
COVID-19 vaccines is unknown. Based on a review
of the literature, methotrexate treatment with doses
commonly used in patients with psoriatic disease
lowers the humoral response to seasonal influenza
and pneumococcal vaccines, and temporary discon-
tinuation of methotrexate for 2 weeks after influenza
immunization improves the immunogenicity of the
seasonal influenza vaccine.43,44 TNFi and tofacitinib
do not significantly affect the humoral immune
response to influenza vaccination but have been
reported to result in both reduced and sufficient
immune responses to the pneumococcal vaccine.44-48
Abatacept,49 ustekinumab,50 and antieIL-17 treat-
ment51-53 do not interfere with the immune response
to either influenza or pneumococcal vaccination,
although large prospective studies of vaccine efficacy
are lacking. No data were available at the time of
analysis for cyclosporine (as used for psoriasis and
other inflammatory diseases), antieIL-23 biologics,
apremilast, or acitretin on the efficacy of any
approved vaccine.
Extrapolating from this literature and based on
current available evidence, the TF recommends that
patients who are to receive an mRNA-based
COVID-19 vaccine continue their biologic or oral
therapies for psoriasis and/or PsA during the
vaccination period (guidance 4.6). Many trials of
COVID-19 treatment and vaccines have excluded
Table II. Vaccine candidates for COVID-19 and available data on vaccination schedule, efficacy, and safety








days 0 and 21
44,000 95% efficacy in preventing
COVID-19 (162 cases in
placebo group, 8 in
BNT162b2 group)
Severe COVID-19: 9 cases in
placebo group, 1 in
BNT162b2 group
d Most common solicited
adverse reactions: injection
site reactions (84.1%), fatigue
(62.9%), headache (55.1%),
muscle pain (38.3%), chills
(31.9%), joint pain (23.6%),
and fever (14.2%)
d Severe adverse reactions
occurred in 0.0% to 4.6% of
participants, were more
frequent after dose 2 than
after dose 1, and were gener-
ally less frequent in partici-
pants $55 years.
d The incidence of serious
adverse events was similar
in the vaccine and placebo
groups (0.6% and 0.5%,
respectively).
d Four cases of Bell palsy in the
vaccine group compared
with no cases in the placebo






























































days 0 and 28
30,400 94.5% efficacy in preventing
COVID-19 (90 cases in
placebo group, 5 in mRNA-
1273 group)
Severe COVID-19: 11 cases in
placebo group, 0 in mRNA-
1273 group
d Most common solicited
adverse reactions: injection
site pain (91.6%), fatigue
(68.5%), headache (63.0%),
muscle pain (59.6%), joint
pain (44.8%), and chills
(43.4%).
d Severe adverse reactions
occurred in 0.2% to 9.7% of
participants, were more
frequent after dose 2 than
after dose 1, and were gener-
ally less frequent in partici-
pants $65 years.
d Unsolicited adverse events
possibly related to vaccine:
d Local lymphadenopathy:
1.1% in the vaccine group
and 0.63% in the placebo
group
d Hypersensitivity: 1.5% in
the vaccine group vs
1.1% placebo group
d Frequency of serious adverse
events was similar in vaccine
and placebo groups (1.0% for
both).
d Four cases of Bell palsy in the
vaccine group compared






















































62.1% (2 standard doses); 90%
(low dose followed by
standard dose); overall,
70.4%
Severe COVID-19: 10 cases in
placebo group, 0 in AZD1222
group
d Serious adverse events: 79 in
treatment and 89 in control
group
d Adverse events: vaccine
(n = 12,021) vs control
(n = 11,724)
d Anaphylactic reaction:






1 dose IM injection; 5 3 1010
viral particles (Ad26.COV2.S)







2 doses of 5 g SARS-CoV-2
rS 1 50 g Matrix-M1 adjuvant
(coformulated), 1 dose each
on days 0 and 21




Participants will receive either
1 or 2 1.0-mg ID injections of
INO-4800 based on results from
phase 2 segment, followed by
EP using the CELLECTRA 2000
device on day 0 and day 28





VIR-7831 given by intravenous
infusion
1360 participants TBD TBD Recruiting
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1264 Gelfand et alpatients with immune-mediated diseases or pa-
tients taking immune-modulating therapy. The TF
encourages the inclusion of patients with psoriatic
disease, including those on systemic treatments, in
future studies of COVID-19 vaccines and treatments
and recommends that patients participate in such
experiments based on shared decision making
among the patient, researcher, and provider (guid-
ance 4.7).
Category 5: What should patients with
psoriatic disease do if they become infected
with SARS-CoV-2?
Major advances have occurred in themanagement
of SARS-CoV-2 since Version 1 of the TF recommen-
dations. For outpatients meeting specific criteria and
at high risk for progressing to severe COVID-19, the
use of monoclonal antibodies specifically directed
against the spike protein of SARS-CoV-2 are recom-
mended (guidance 5.2).54-58 For hospitalized pa-
tients meeting specific criteria, in addition to
remdesivir and dexamethasone, baricitinib in com-
bination with remdesivir is an option as because
reduces recovery time and new infections in hospi-
talized patients with COVID-19 compared to remde-
sivir alone.59 However, baricitinib had no mortality
benefit, can be prothrombotic, and is recommended
only when corticosteroids cannot be used.59,60
Furthermore, the remdesivir efficacy is modest, and
international trials did not find mortality benefit.61,62
Additional evidence suggests that hydroxychlor-
oquine is not effective for the prevention or treat-
ment of COVID-19; therefore, the TF emphasizes that
its use be restricted to clinical trials (guidance
5.4.1).63-67 The evidence that convalescent plasma
is effective for COVID-19 is limited despite the FDA
EUA; therefore, the TF recommends that it be used
primarily in clinical trials (guidance 5.4.2).68,69
Ivermectin has in vitro activity against SARS-CoV-2;
however, doses up to 100 times higher than those
approved for use in humans would be required to
achieve antiviral effects against COVID-19, raising
safety concerns even if therapeutic levels could
feasibly be achieved.70-73 Therefore, the TF recom-
mends ivermectin be used only in the setting of a
clinical trial (guidance 5.4.3).
Based on limited available data and to be consis-
tent with prescribing information, it may be prudent
to hold treatments that target the immune system in
the setting of suspected or confirmed SARS-CoV-2
infection, but the ultimate decision should be made
case by case. Patients with psoriatic disease should
be aware that infection with SARS-CoV-2 may result
in a flare of psoriasis, including pustular flares
(guidance 5.6).74-81Patients with psoriatic disease who become in-
fected with SARS-CoV-2 should follow Centers for
Disease Control and Prevention guidance on home
isolation and discuss with their health care providers
when they can end home isolation (guidance 5.7;
Version 1, Supplemental Table IX available via
Mendeley at https://doi.org/10.17632/w5m8jf94m8.
2).1,82-84 In the event that someone with psoriatic
disease has close contact (Version 1, Supplemental
Table X) with an individual with suspected or
confirmed SARS-CoV-2 infection, he or she should
follow local public health authority guidance for the
recommended duration of quarantine.1 The Centers
for Disease Control and Prevention recommends a
quarantine period of 14 days after last contact with a
person who has COVID-19, assuming one remains
asymptomatic, but offers an option to shorten
quarantine to end after day 10 from last contact or
day 7 with appropriately timed diagnostic testing
(guidance 5.8).85 Individuals who have had COVID-
19 within the past 3 months do not need to
quarantine after close contact with someone who is
infected, as long as they do not develop symptoms
again.86 The decision regarding continuing or hold-
ing psoriasis treatments during a period of quaran-
tine should be individualized on a case-by-case basis
between patient and provider.
Resumption of psoriasis and/or PsA treatments
held during SARS-CoV-2 infection should be decided
on a case-by-case basis (guidance 5.5). The persis-
tence of 1 or more symptoms of COVID-19, such as
fatigue or joint pain, beyond the acute phase of the
illness can occur87 and may complicate the decision
to restart psoriasis or PsA medications. Therefore,
shared decision making between the patient and
provider(s) is recommended (guidance 2.5).
DISCUSSION
The NPF COVID-19 TF guidance statements
serve to promote optimal management of psoriatic
disease during the pandemic. Several limitations are
acknowledged. First, the TF did not formally grade
the strength of our recommendations.88 With the
exception of guidance statements 4.4, 4.5, 5.2,
5.4.1, and 5.4.2, which are based on large-scale
randomized controlled trials, the evidence behind
many guidance statements is limited in quality or
quantity. Large-scale, longer-term, population-
based studies of patients with psoriatic disease
(particularly those with increased COVID-19 risk
due to age and/or comorbidity), with appropriate
comparator groups, adjustment for relevant con-
founding variables, and complete ascertainment of
clinically important COVID-19 outcomes are ur-
gently needed.89 Second, the guidance is intended
J AM ACAD DERMATOL
VOLUME 84, NUMBER 5
Gelfand et al 1265to be neither proscriptive nor comprehensive. The
ultimate judgment regarding how these recommen-
dations should be followed is best left with the
treating clinician and the patient in light of the
circumstances presented by the individual patient
and the variability and biological behavior of the
disease and therapeutics.
The recommendations are a living document that
will be updated and amendedwhen necessary by the
rapidly evolving science of COVID-19. Readers are
encouraged to visit https://www.psoriasis.org/
covid-19-resource-center regularly for the latest
guidance from the TF to promote optimal care and
outcomes for patients with psoriatic disease during
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